A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

NCT04641754 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: WX-0593 Tablets

Sponsor

Qilu Pharmaceutical Co., Ltd.